CRANBURY NEW JERSEY HOT BED OF PHARMA
Image from CBC
Rocket Pharmaceuticals’ Research and Development (R&D) and Manufacturing Facility, Cranbury
https://rumble.com/v26t58u-namagen-funding-proves-nih-knew-of-covid-in-september-2019.html Please watch my video on another Pharma company from Cranbury NJ. Nemagen. Nema is the satanic version of Amen (the letters in reverse). They pave their roads with evil. Shine a light.
“Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support the production of its pipeline of lentivirus and adeno-associated virus (AAV) gene therapies.
Project Type
New research and development (R&D) and manufacturing facility
Rocket Pharmaceuticals develops genetic therapies
for complex and rare childhood, genetic therapies
pipeline includes both AAV and LVV programmes.
pipeline of lentivirus and adeno-associated virus (AAV) gene therapies.
AAV-based gene therapy, RP-A501, for the treatment of Danon disease, a heart-related disease.
The Cranbury facility will play a vital role in the company’s objective to deliver five curative gene therapies for the treatment of rare diseases by 2025.
Funding details
“Rocket Pharmaceuticals plans to begin the first current good manufacturing practice (cGMP) production at the facility in 2021.”
ÈRocket Pharmaceuticals secured approximately $300m through a public equity offering of 6,035,714 shares of its common stock in December 2020.
The company will use a portion of the funds raised through the public equity offering to build-out the new facility and develop Rocket’s gene therapies pipeline for rare diseases filing for the marketing authorisation of RP-L201 in the US and Europe.
Investment banking firms, including JP Morgan, BofA Securities, Piper Sandler and SVB Leerink served as the joint book-running managers for the public offering.
Rocket’s RP-A501 AAV-based gene therapy for Danon disease
Preliminary data indicated that the low dose RP-A501 cohort remained well-tolerated and offered early evidence of clinical benefit. “
(LL: WELL TOLERATED IS THAT THE NEW SAFE? AND CLINICAL BENEFIT IS THE NEW EFFECTIVE?)
Marketing commentary on Rocket Pharmaceuticals
“Rocket Pharmaceuticals is a clinical-stage biotechnology firm focused on the development of a pipeline of genetic therapies for complex and rare childhood diseases.
In March 2020, Rocket Pharmaceuticals entered a research partnership agreement with Forty Seven, a clinical-stage immuno-oncology company, for the treatment of Fanconi Anaemia, a rare paediatric genetic disorder that results in bone marrow failure.
Rocket’s genetic therapies pipeline includes both adeno-associated viral vector and lentiviral vector (LVV) approaches for the treatment of rare genetic disorders.
The company leverages LVV-based programmes for the treatment of Fanconi Anemia, Leukocyte Adhesion Deficiency-I, a rare genetic disease that leads to malfunctioning of the immune system, Pyruvate Kinase Deficiency, a rare red blood cell disorder and Infantile Malignant Osteopetrosis, a rare, genetic bone disorder. The company announced that its first AAV-based programme targets Danon disease.”
Do we need to be saved from rare diseases? Will we trust their products for it? Who are they going to be left to market their products to?
Our world needs to be save from the NOT-RARE ill effects of mRNA or genetic therapeutics already on& the market. Are pharmaceuticals ever going to be trusted again?
On another note JPMorgan reaches $290 million settlement with Jeffrey Epstein victims.
Perhaps before raising money for more of these genetic ‘vaccines’ we can address the carnage, death, and damage from the current mRNA technology.
Thanks for reporting.